IP Library Granted Patent US 12679902
Granted Patent B2
US 12679902 · App. 17/626,345 · Granted Jul 14, 2026

Method for producing cell population containing CAR-expressing immune cells

Inventors: Yozo Nakazawa (Matsumoto, JP); Shigeki Yagyu (Kyoto, JP); Miyuki Tanaka (Matsumoto, JP); Kayoko Nakamura (Matsumoto, JP); Masahiro Okada (Sagamihara, JP); Makoto Kondo (Kawasaki, JP); Tomokuni Shigeura (Kawasaki, JP); Shogo Hirota (Tokyo, JP)
Assignees: SHINSHU UNIVERSITY; KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION; BRIGHTPATH BIOTHERAPEUTICS CO., LTD.
C07K16/32A61K40/11A61K40/31A61K40/4205A61K40/4211A61K40/422A61P35/00C07K14/70532C07K14/70578C07K14/715C12N5/0636A61K38/00C07K2317/622C07K2317/76C07K2319/02C07K2319/03C07K2319/33C12N2502/11C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12679902
App. No.
17/626,345
Granted
Jul 14, 2026
Kind
B2
Abstract

The present disclosure includes a method of producing a cell population containing Chimeric Antigen Receptor (CAR)-expressing immune cells, comprising co-culturing CAR-expressing immune cells and cells expressing a target antigen of the CAR, wherein the CAR-expressing immune cells are cells into which a CAR gene has been introduced and the target antigen-expressing cells are normal blood cells that have been engineered to express the target antigen.

Claims (17)

1 . A method of producing a cell population containing Chimeric Antigen Receptor (CAR)-expressing immune cells, comprising co-culturing CAR-expressing immune cells and cells expressing a target antigen of the CAR, wherein the CAR-expressing immune cells are cells into which a CAR gene has been introduced and the target antigen-expressing cells are cells that have been prepared by gene transfer into peripheral blood mononuclear cells (PBMCs), wherein the target antigen is Human epidermal growth factor receptor 2 (HER2) or Ephrin type-B receptor 4 (EPHB4).

2 . The method according to claim 1 , wherein the immune cells are lymphocytes.

3 . The method according to claim 1 , wherein the immune cells are T cells.

4 . The method according to claim 1 , wherein the CAR-expressing immune cells are cells that have been prepared by gene transfer into peripheral blood mononuclear cells (PBMCs).

5 . The method according to claim 1 , further comprising preparing the CAR-expressing immune cells.

6 . The method according to claim 5 , wherein the CAR-expressing immune cells are prepared by gene transfer into PBMCs.

7 . The method according to claim 5 , wherein the CAR-expressing immune cells are prepared by the piggyflac transposon-mediated method.

8 . The method according to claim 1 , wherein the target antigen-expressing cells are cells into which one or more genes of one or more co-stimulatory molecules have been introduced.

9 . The method according to claim 1 , wherein the gene transfer includes transfer of a target antigen gene.

10 . The method according to claim 1 , further comprising preparing the target antigen-expressing cells.

11 . The method according to claim 10 , wherein the target antigen-expressing cells are prepared from PBMCs.

12 . The method according to claim 11 , wherein the target antigen-expressing cells are prepared by gene transfer into PBMCs.

13 . The method according to claim 12 , wherein the gene transfer includes transfer of a target antigen gene.

14 . The method according to claim 8 , wherein the one or more co-stimulatory molecules are selected from CD40, CD80, 4-1BBL, and OX40L.

15 . A cell population containing Chimeric Antigen Receptor (CAR)-expressing immune cells produced by the method according to claim 1 .

16 . A method for treating cancer, comprising administering the cell population according to claim 15 to a subject.

17 . The method according to claim 16 , wherein the cancer is a solid tumor.